Clinical Trial Update: Cardiac Safety Study of Brentuximab Vedotin (SGN-35) [Phase 1]

View source ↗

Summary

Phase 1 cardiac safety study of brentuximab vedotin (SGN-35) has completed, providing early safety data in lymphoma patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic | Phase 1 | Status: COMPLETED